BioTime, Inc. (NYSE: BTX) and its subsidiary Cell Cure Neurosciences Ltd. today announced that Cell Cure has been awarded a grant for 2012 of 5.04 million Shekels (approximately $1.33 million) from Israel's Office of the Chief Scientist to help finance the development of OpRegen, a cell-based therapeutic product in development by Cell Cure for the treatment of age-related macular degeneration. Cell Cure's plans for the development of OpRegen® include filing an application to commence human clinical trials in 2013.
(c) 2012 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. [Photo from flicker user zeevveez]
0 comments
- Get Livefyre
- FAQ
Newest | Oldest
